NOV 30, 2021 11:00 AM PST

Clinical value of measurable residual disease assessment in multiple myeloma

Sponsored by: Cytognos
C.E. Credits: P.A.C.E. CE Florida CE

Event Date & Time
Date:  November 30, 2021
Time: 11:00am (PST),  2:00pm (EST)
In recent years, Measurable Residual Disease (MRD) assessment in Multiple Myeloma (MM) has gained increasing relevance. After more than a decade of active research in the field, new drugs and treatment strategies have emerged. They have significantly modified the way we approach the disease by transforming deep and sustained responses into a realistic goal.
Thanks to the technological development, classic detection approaches like conventional flow cytometry or ASO-PCR, have evolved into next generation methodologies that have supported MRD to become a more widely used prognostic indicator and clinical decision-making tool. Other alternative methods, like liquid biopsy or mass spectrometry, are also making their way to the front-line of treatment monitoring, but their efficient integration in patient management is yet to be defined.
Lastly, substantial efforts are ongoing to recognize the value of standardization of MRD assessment. Following standardized methodologies can accelerate the obtention of clinically meaningful results and thus, lead to further optimized therapies.
Learning Objectives:
  • Analyze the bases of MRD detection in MM patients with available methodologies.
  • Discuss the clinically useful information that MRD provides and how MRD testing can be incorporated in routine clinical practice.
  • Assess recent advances and new opportunities in the field of Multiple Myeloma patient monitoring.
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

You May Also Like
Loading Comments...
  • See More